Literature DB >> 21156789

Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK.

Sahdeo Prasad1, Vivek R Yadav, Ramaswamy Kannappan, Bharat B Aggarwal.   

Abstract

Discovery of the molecular targets of traditional medicine and its chemical footprints can validate the use of such medicine. In the present report, we investigated the effect of ursolic acid (UA), a pentacyclic triterpenoid found in rosemary and holy basil, on apoptosis induced by TRAIL. We found that UA potentiated TRAIL-induced apoptosis in cancer cells. In addition, UA also sensitized TRAIL-resistant cancer cells to the cytokine. When we investigated the mechanism, we found that UA down-regulated cell survival proteins and induced the cell surface expression of both TRAIL receptors, death receptors 4 and 5 (DR4 and -5). Induction of receptors by UA occurred independently of cell type. Gene silencing of either receptor by small interfering RNA reduced the apoptosis induced by UA and the effect of TRAIL. In addition, UA also decreased the expression of decoy receptor 2 (DcR2) but not DcR1. Induction of DRs was independent of p53 because UA induced DR4 and DR5 in HCT116 p53(-/-) cells. Induction of DRs, however, was dependent on JNK because UA induced JNK, and its pharmacologic inhibition abolished the induction of the receptors. The down-regulation of survival proteins and up-regulation of the DRs required reactive oxygen species (ROS) because UA induced ROS, and its quenching abolished the effect of the terpene. Also, potentiation of TRAIL-induced apoptosis by UA was significantly reduced by both ROS quenchers and JNK inhibitor. In addition, UA was also found to induce the expression of DRs, down-regulate cell survival proteins, and activate JNK in orthotopically implanted human colorectal cancer in a nude mouse model. Overall, our results showed that UA potentiates TRAIL-induced apoptosis through activation of ROS and JNK-mediated up-regulation of DRs and down-regulation of DcR2 and cell survival proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156789      PMCID: PMC3037668          DOI: 10.1074/jbc.M110.183699

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.

Authors:  R D Meng; E R McDonald; M S Sheikh; A J Fornace; W S El-Deiry
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

2.  Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells.

Authors:  Y H Choi; J H Baek; M A Yoo; H Y Chung; N D Kim; K W Kim
Journal:  Int J Oncol       Date:  2000-09       Impact factor: 5.650

3.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

Authors:  R Takimoto; W S El-Deiry
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

4.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.

Authors:  B Gliniak; T Le
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

Review 5.  Reactive oxygen species and programmed cell death.

Authors:  M D Jacobson
Journal:  Trends Biochem Sci       Date:  1996-03       Impact factor: 13.807

6.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.

Authors:  S Hinz; A Trauzold; L Boenicke; C Sandberg; S Beckmann; E Bayer; H Walczak; H Kalthoff; H Ungefroren
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

7.  Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication.

Authors:  D K Kim; J H Baek; C M Kang; M A Yoo; J W Sung; H Y Chung; N D Kim; Y H Choi; S H Lee; K W Kim
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

8.  Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells.

Authors:  K Subbaramaiah; P Michaluart; M B Sporn; A J Dannenberg
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

9.  Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

Authors:  M A Grotzer; A Eggert; T J Zuzak; A J Janss; S Marwaha; B R Wiewrodt; N Ikegaki; G M Brodeur; P C Phillips
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

10.  Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance.

Authors:  N Ozören; M J Fisher; K Kim; C X Liu; A Genin; Y Shifman; D T Dicker; N B Spinner; N A Lisitsyn; W S El-Deiry
Journal:  Int J Oncol       Date:  2000-05       Impact factor: 5.650

View more
  38 in total

1.  Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway.

Authors:  Ji Hye Kim; Byoungduck Park; Subash C Gupta; Ramaswamy Kannappan; Bokyung Sung; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

Review 2.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

3.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

4.  Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.

Authors:  Hu Xiaowen; Sun Yi
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

5.  Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells.

Authors:  Sung-Chul Lim; Ho Jong Jeon; Keun Hong Kee; Mi Ja Lee; Ran Hong; Song Iy Han
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

6.  Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.

Authors:  Hairong Cheng; Bo Hong; Lanlan Zhou; Joshua E Allen; Guihua Tai; Robin Humphreys; David T Dicker; Yingqiu Y Liu; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

7.  Pomolic acid induces apoptosis in SK-OV-3 human ovarian adenocarcinoma cells through the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways.

Authors:  Ki Hyun Yoo; Jong-Hwa Park; DO Kyung Lee; Yuan Yuan Fu; Nam In Baek; In Sik Chung
Journal:  Oncol Lett       Date:  2012-10-22       Impact factor: 2.967

8.  Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.

Authors:  Eun Young Kim; Ji Sun Yu; Mihi Yang; An Keun Kim
Journal:  Mol Cells       Date:  2012-12-04       Impact factor: 5.034

9.  The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway.

Authors:  Sung-Chul Lim; Keshab Raj Parajuli; Song Iy Han
Journal:  Tumour Biol       Date:  2015-11-28

10.  Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.

Authors:  Zhongling Zhu; Shuangshuang Du; Fengxia Ding; Shanshan Guo; Guoguang Ying; Zhao Yan
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.